Improving Wound Management: AdTec Healthcare’s SteriPlas Technology Explained

Wounds typically heal within 4 to 6 weeks. However, chronic wounds do not heal within this period, which can result in serious health complications and higher healthcare expenses. But what if there were a safer method to accelerate the healing process? Adtec Healthcare is leading the charge in tackling this critical challenge with its groundbreaking SteriPlas technology, which harnesses the power of cold plasma to improve wound healing and manage infections effectively.

Cold Plasma: A Game Changer in Infection Management

Adtec’s SteriPlas technology has demonstrated remarkable efficacy in managing infections, particularly in chronic wounds. One of the key advantages of using cold plasma over traditional treatments lies in its unique physical mode of action. Unlike conventional antibiotics, which can be ineffective against biofilm-protected bacteria, SteriPlas can penetrate and destroy all bacterial species, regardless of whether they are Gram-positive or Gram-negative.

As Mary McGovern, CEO of Adtec Healthcare, states, “Our SteriPlas technology is revolutionary in how it addresses wound healing. By utilizing a physical mode of action, we not only eliminate bacteria effectively but also do so without creating resistance, a critical challenge in today’s healthcare landscape.”

The technology is particularly effective against biofilms, which complicate wound healing processes. Biofilms consist of clusters of bacteria that form a protective layer, rendering conventional antibiotic therapy less effective. The SteriPlas treatment can achieve the elimination of bacteria within biofilm in a single session lasting as little as 2 minutes. Moreover, the cold plasma generated by SteriPlas is low-energy, operating at 2.4GHz and microwave-generated, ensuring it is safe and effective without side effects.

Cost-Effectiveness of SteriPlas

Recent Health Economics data indicates that SteriPlas is significantly more cost-effective than conventional therapies. The ability to destroy bacteria quickly accelerates the healing process, thereby reducing hospitalization time and associated costs. For example, a patient suffering from a diabetic foot ulcer could be under hospital care for up to 12 months with little progress using standard treatments. In contrast, SteriPlas can achieve complete healing in as little as a few weeks with bi-weekly treatments.

Adtec’s innovative technology not only shortens appointment durations but also alleviates the financial burden on healthcare facilities. As the SteriPlas treatment can be seamlessly integrated into existing treatment protocols, many healthcare professionals initially use it as an adjunct therapy to combat stalled infections. However, due to its effectiveness, they often abandon conventional therapies altogether.

Real-World Clinical Outcomes

With over 80 peer-reviewed studies and 8 randomized controlled trials (RCTs) conducted, SteriPlas has made a significant impact on patient outcomes in wound care and infection prevention. Its efficacy has led clinicians to utilize SteriPlas not only for chronic, deep infections but also for superficial wounds, preventing their progression into more severe conditions.

Adtec Healthcare is keen to share these findings with the MedTech World community to encourage broader adoption.

“We believe that collaboration and knowledge sharing within the MedTech community can drive innovation and improve patient care on a global scale,” McGovern adds.

New Indications for Surgical Infection Prevention

Adtec Healthcare is expanding the application of SteriPlas to include post-operative implant treatment. The technology has shown promising results in preventing surgical site infections (SSIs), such as deep sternal wound infections and infections related to Left Ventricular Assist Devices (LVADs). These types of infections are notoriously challenging to treat with traditional therapies due to their location within deep cavities.

SteriPlas’s ability to propel cold plasma via gas flow allows it to reach biofilms and bacterial colonies in hard-to-access areas, effectively destroying them. This innovative approach opens doors to numerous potential applications, including implant infections and other SSI conditions yet to be explored.

Combating Antimicrobial Resistance (AMR)

Given the rising issue of antimicrobial resistance (AMR), the positioning of cold plasma as a viable alternative to antibiotics is crucial. The SteriPlas technology provides a physical mode of action that does not lead to the development of bacterial resistance, making it an essential tool in combating AMR.

“By using SteriPlas on infections that have not responded to antibiotics, we can reverse the damage caused by infections and promote healing. Our cold plasma technology is broad-spectrum and delivers a robust antibacterial effect that significantly reduces AMR rates,” McGovern explains.

Global Distribution Strategy

Adtec Healthcare has successfully established relationships with distributors in over 10 countries. However, challenges remain in educating healthcare providers about this innovative technology. Many regions still rely on outdated treatments due to financial constraints or loyalty to conventional methods.

To facilitate the adoption of SteriPlas, Adtec Healthcare offers free trials to hospitals and distributors, allowing them to experience the benefits firsthand. This strategy has proven effective in accelerating the acceptance and integration of SteriPlas into standard treatment protocols.

Future Prospects and Innovation

As Adtec Healthcare looks to the future, it aims to expand its reach to markets such as the USA, Asia, and Australia, pending necessary approvals. The company is committed to bringing the benefits of cold plasma technology to areas yet to explore its potential.

With two papers in the journal Health Economics highlighting the cost-effectiveness of SteriPlas in treating chronic infections, Adtec is well-positioned to advocate for the integration of this technology into healthcare systems worldwide.

Takeaway

Adtec Healthcare’s SteriPlas technology is set to transform wound care and infection management. By utilizing the unique properties of cold plasma, SteriPlas tackles the significant challenges associated with chronic wounds and the increasing issue of antimicrobial resistance. Through partnerships with the MedTech World community and a commitment to global expansion, Adtec aims to improve patient outcomes and advance the field of healthcare.

Join MedTech Malta 2024!

Mary McGovern will be speaking on the panel, ‘How We Do It—Investors and Entrepreneurs Together,’ at MedTech Malta 2024. Don’t miss this chance to hear first-hand insights into the collaboration between innovators and investors in the MedTech industry. Reserve your spot now to connect with industry experts, discover emerging trends, and explore new opportunities driving advancements in healthcare. Register today and become part of the conversation at MedTech Malta 2024!